<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Rocket Pharmaceuticals Inc — News on 6ix</title>
    <link>https://6ix.com/company/rocket-pharmaceuticals-inc</link>
    <description>Latest news and press releases for Rocket Pharmaceuticals Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 28 Apr 2026 11:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/rocket-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b60378dffbe2df113e4c.webp</url>
      <title>Rocket Pharmaceuticals Inc</title>
      <link>https://6ix.com/company/rocket-pharmaceuticals-inc</link>
    </image>
    <item>
      <title>Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher</title>
      <link>https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-announces-dollar180-million-sale-of-priority-review-voucher</link>
      <guid isPermaLink="true">https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-announces-dollar180-million-sale-of-priority-review-voucher</guid>
      <pubDate>Tue, 28 Apr 2026 11:00:00 GMT</pubDate>
      <description>CRANBURY, N.J., April 28, 2026--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced a strengthened financial position following the sale of its Rare Pediatric Disease Priority Review Voucher (PRV).</description>
    </item>
    <item>
      <title>Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)</title>
      <link>https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-announces-fda-approval-of-kresladitm-for-pediatric-patients-with-severe-leukocyte-adhesion-deficiency-i-lad-i</link>
      <guid isPermaLink="true">https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-announces-fda-approval-of-kresladitm-for-pediatric-patients-with-severe-leukocyte-adhesion-deficiency-i-lad-i</guid>
      <pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
      <description>First FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2 Severe LAD-I is an ultra-rare, life-threatening pediatric</description>
    </item>
    <item>
      <title>Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress</title>
      <link>https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-highlights-recent-progress</link>
      <guid isPermaLink="true">https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-highlights-recent-progress</guid>
      <pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
      <description>Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026 KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA date Dosing of first</description>
    </item>
    <item>
      <title>Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-participate-44th-annual-jp-morgan-healthcare-conference-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-participate-44th-annual-jp-morgan-healthcare-conference-2026</guid>
      <pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
      <description>CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable</description>
    </item>
    <item>
      <title>Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference</title>
      <link>https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-participate-8th-annual-evercore-healthcare-conference-2025-11</link>
      <guid isPermaLink="true">https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-participate-8th-annual-evercore-healthcare-conference-2025-11</guid>
      <pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
      <description>CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable</description>
    </item>
    <item>
      <title>Neurvati Neurosciences Appoints Carlos Martin as Chief Commercial Officer</title>
      <link>https://6ix.com/company/rocket-pharmaceuticals-inc/news/neurvati-neurosciences-appoints-carlos-martin-as-chief-commercial-officer</link>
      <guid isPermaLink="true">https://6ix.com/company/rocket-pharmaceuticals-inc/news/neurvati-neurosciences-appoints-carlos-martin-as-chief-commercial-officer</guid>
      <pubDate>Thu, 13 Nov 2025 12:00:00 GMT</pubDate>
      <description>Neurvati Neurosciences, the neuroscience development platform of Blackstone Life Sciences, today announced the appointment of Carlos Martin as Chief Commercial Officer (CCO). Martin brings more than 20 years of leadership experience across global biopharmaceutical markets, with a proven record of building commercial organizations, launching transformative therapies, and strengthening pipeline valuation in highly innovative areas such as gene therapy, radiopharma, oncology, cardiology, and rare d</description>
    </item>
    <item>
      <title>Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress</title>
      <link>https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-reports-third-quarter-2025-financial-results-and-highlights</link>
      <guid isPermaLink="true">https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-reports-third-quarter-2025-financial-results-and-highlights</guid>
      <pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
      <description>Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026 KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA date Leadership updates</description>
    </item>
    <item>
      <title>Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)</title>
      <link>https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-announces-fda-acceptance-bla-resubmission-kresladitm-treatment</link>
      <guid isPermaLink="true">https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-announces-fda-acceptance-bla-resubmission-kresladitm-treatment</guid>
      <pubDate>Tue, 14 Oct 2025 04:00:00 GMT</pubDate>
      <description>Prescription Drug User Fee Act (PDUFA) target action date is March 28, 2026 All primary and secondary endpoints were met, and KRESLADI™ was well tolerated</description>
    </item>
    <item>
      <title>Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</link>
      <guid isPermaLink="true">https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</guid>
      <pubDate>Fri, 10 Oct 2025 04:00:00 GMT</pubDate>
      <description>CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable</description>
    </item>
    <item>
      <title>Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-participate-upcoming-investor-conferences-2025-08-28</link>
      <guid isPermaLink="true">https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-participate-upcoming-investor-conferences-2025-08-28</guid>
      <pubDate>Thu, 28 Aug 2025 04:00:00 GMT</pubDate>
      <description>CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable</description>
    </item>
    <item>
      <title>Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease</title>
      <link>https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-announces-fda-has-lifted-clinical-hold-pivotal-phase-2-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-announces-fda-has-lifted-clinical-hold-pivotal-phase-2-trial</guid>
      <pubDate>Wed, 20 Aug 2025 04:00:00 GMT</pubDate>
      <description>CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable</description>
    </item>
    <item>
      <title>Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress</title>
      <link>https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-reports-second-quarter-2025-financial-results-and-highlights</link>
      <guid isPermaLink="true">https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-reports-second-quarter-2025-financial-results-and-highlights</guid>
      <pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
      <description>Prioritizing development of RP-A501 (Danon disease), RP-A601 (PKP2-ACM), and RP-A701 (BAG3-DCM) to advance AAV cardiovascular gene therapy platform for</description>
    </item>
    <item>
      <title>Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs</title>
      <link>https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-announces-strategic-corporate-reorganization-and-pipeline</link>
      <guid isPermaLink="true">https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-announces-strategic-corporate-reorganization-and-pipeline</guid>
      <pubDate>Thu, 24 Jul 2025 04:00:00 GMT</pubDate>
      <description>Restructuring pipeline to focus on AAV cardiovascular platform (Danon disease, PKP2-ACM, BAG3-DCM) and regulatory activities for KRESLADI™ (severe LAD-I),</description>
    </item>
    <item>
      <title>Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy</title>
      <link>https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-receives-fda-regenerative-medicine-advanced-therapy-rmat</link>
      <guid isPermaLink="true">https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-receives-fda-regenerative-medicine-advanced-therapy-rmat</guid>
      <pubDate>Thu, 17 Jul 2025 04:00:00 GMT</pubDate>
      <description>CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and</description>
    </item>
    <item>
      <title>Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy</title>
      <link>https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-announces-fda-ind-clearance-rp-a701-treatment-bag3-associated</link>
      <guid isPermaLink="true">https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-announces-fda-ind-clearance-rp-a701-treatment-bag3-associated</guid>
      <pubDate>Mon, 30 Jun 2025 04:00:00 GMT</pubDate>
      <description>RP-A701 is a first-in-class gene therapy for the treatment of BAG3-associated dilated cardiomyopathy BAG3-associated dilated cardiomyopathy is a rare,</description>
    </item>
    <item>
      <title>Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease</title>
      <link>https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-provides-update-phase-2-clinical-trial-rp-a501-danon-disease</link>
      <guid isPermaLink="true">https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-provides-update-phase-2-clinical-trial-rp-a501-danon-disease</guid>
      <pubDate>Tue, 27 May 2025 04:00:00 GMT</pubDate>
      <description>Conference call to be held later today at 8:30 a.m. ET CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated,</description>
    </item>
    <item>
      <title>Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy</title>
      <link>https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-presents-preliminary-data-phase-1-clinical-trial-rp-a601-pkp2</link>
      <guid isPermaLink="true">https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-presents-preliminary-data-phase-1-clinical-trial-rp-a601-pkp2</guid>
      <pubDate>Thu, 15 May 2025 04:00:00 GMT</pubDate>
      <description>RP-A601 was generally well-tolerated at a dose of 8.0E13 GC/kg with no dose-limiting toxicities in all three patients with up to 12 months follow-up RP-A601</description>
    </item>
    <item>
      <title>Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy</title>
      <link>https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-data-phase-1</link>
      <guid isPermaLink="true">https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-data-phase-1</guid>
      <pubDate>Fri, 09 May 2025 04:00:00 GMT</pubDate>
      <description>CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable</description>
    </item>
    <item>
      <title>Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress</title>
      <link>https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-reports-first-quarter-2025-financial-results-and-highlights</link>
      <guid isPermaLink="true">https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-reports-first-quarter-2025-financial-results-and-highlights</guid>
      <pubDate>Thu, 08 May 2025 04:00:00 GMT</pubDate>
      <description>Phase 2 pivotal study of RP-A501 for Danon disease is ongoing; Program update expected mid-year 2025 Initial data from the Phase 1 study of RP-A601 for</description>
    </item>
    <item>
      <title>Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference</title>
      <link>https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-participate-24th-annual-needham-virtual-healthcare-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/rocket-pharmaceuticals-inc/news/rocket-pharmaceuticals-participate-24th-annual-needham-virtual-healthcare-conference</guid>
      <pubDate>Thu, 03 Apr 2025 04:00:00 GMT</pubDate>
      <description>CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable</description>
    </item>
  </channel>
</rss>